Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 4/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | BRS3 | P32247 | 1/20 | 0.37 |
| ▸ | LATS1 | O95835 | 2/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957148 | 1.00 | CYP17A1 (0.47) | CYP17A1NAMPTATRRAB9AMETAP1 | |
| SCHEMBL1197794 | 0.89 | CYP17A1 (0.47) | CYP17A1NAMPTATRRAB9AMETAP1 | |
| SCHEMBL29957527 | 0.89 | CYP17A1 (0.47) | CYP17A1NAMPTATRRAB9AMETAP1 | |
| SCHEMBL4725743 | 0.85 | NAMPT (0.43) | CYP17A1NAMPTATRRAB9AMETAP1 | |
| SCHEMBL3537542 | 0.84 | NAMPT (0.42) | CYP17A1NAMPTATRRAB9AMETAP1 | |
| SCHEMBL3537539 | 0.84 | NAMPT (0.42) | CYP17A1NAMPTATRRAB9AMETAP1 | |
| SCHEMBL14291975 | 0.84 | CYP17A1 (0.42) | CYP17A1NAMPTATRRAB9AMETAP1 | |
| SCHEMBL6604919 | 0.84 | CYP17A1 (0.38) | CYP17A1NAMPTATRRAB9AMETAP1 | |
| SCHEMBL18522430 | 0.83 | NAMPT (0.50) | CYP17A1NAMPTATRRAB9AMETAP1 | |
| SCHEMBL4075130 | 0.83 | CCNC (0.46) | CYP17A1NAMPTATRRAB9AMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197899-A1 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| CN-117940168-A | 2-Amino-4-carboxamide-benzazepine immunoconjugates and uses thereof | 博尔特生物治疗药物有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4313161-A1 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20220267349-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-08-25 | — | — | US | disclosed |
| EP-4034239-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2022-08-03 | — | — | EP | disclosed |
| CN-114401969-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20210107921-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-15 | — | — | US | disclosed |
| WO-2021058416-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-04-01 | — | — | WO | disclosed |
| US-10907197-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3190888-B1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20060135511-A1 | Benzodiazepine cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-06-22 | — | — | US | disclosed |
| EP-1641423-A2 | BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050256098-A1 | CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2005-11-17 | — | — | US | disclosed |
| US-6953790-B2 | CGRP receptor antagonists | MERCK & CO., INC. (US) | 2005-10-11 | — | — | US | disclosed |
| WO-2005013894-A2 | BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20040229861-A1 | CGRP receptor antagonists | MERCK SHARP & DOHME LLC | 2004-11-18 | — | — | US | disclosed |
| EP-1226119-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6479512-B1 | TO TREAT TYROSINE KINASE-DEPENDENT DISEASES AND CONDITIONS, SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, ETC. | MERCK & CO., INC. | 2002-11-12 | — | — | US | disclosed |
| EP-1226119-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO. INC. (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001028993-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO. INC. (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135511-A1 | Benzodiazepine cgrp receptor antagonists | NPY1R, NPY2R, CCKBR | CYP17A1 2652/4885NAMPT 4387/4885ATR 3640/4885 |
| US-20210107921-A1 | HETEROCYCLIC COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1, CCNY | CYP17A1 2708/4885NAMPT 998/4885ATR 974/4885 |
| US-20040229861-A1 | CGRP receptor antagonists | CCKBR, CCKAR, CALCRL | CYP17A1 3607/4885NAMPT 3684/4885ATR 3941/4885 |
| US-10907197-B2 | Probes for imaging huntingtin protein | HTT, HYPK, FABP7 | CYP17A1 3704/4885NAMPT 2774/4885ATR 4673/4885 |
| US-20240197899-A1 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | AADAC, BRD4, IDO2 | CYP17A1 2587/4885NAMPT 1849/4885ATR 4178/4885 |
| US-20220267349-A1 | HETEROCYCLIC COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1, CCNY | CYP17A1 2708/4885NAMPT 998/4885ATR 974/4885 |
| US-20050256098-A1 | CGRP receptor antagonists | CCKBR, BDKRB1, BDKRB2 | CYP17A1 3781/4885NAMPT 3101/4885ATR 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.